loading
Schlusskurs vom Vortag:
$26.60
Offen:
$26.64
24-Stunden-Volumen:
2.38M
Relative Volume:
3.10
Marktkapitalisierung:
$2.32B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-18.48
EPS:
-1.45
Netto-Cashflow:
$-134.36M
1W Leistung:
+0.56%
1M Leistung:
-11.35%
6M Leistung:
-35.26%
1J Leistung:
-15.22%
1-Tages-Spanne:
Value
$26.30
$27.50
1-Wochen-Bereich:
Value
$25.20
$27.50
52-Wochen-Spanne:
Value
$25.20
$47.73

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
Firmenname
Ideaya Biosciences Inc
Name
Telefon
650-443-6209
Name
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
124
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
IDYA's Discussions on Twitter

Vergleichen Sie IDYA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
IDYA 26.79 2.32B 23.38M -155.22M -134.36M -1.45
VRTX 450.97 116.38B 10.63B -479.80M -1.35B 13.33
REGN 738.00 82.09B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.14B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.25B 3.30B -501.07M 1.03B 11.54

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-08-08 Eingeleitet SVB Securities Outperform
2023-05-24 Eingeleitet Goldman Buy
2023-04-24 Hochstufung Stifel Hold → Buy
2023-03-23 Eingeleitet Berenberg Buy
2023-02-28 Eingeleitet RBC Capital Mkts Outperform
2022-12-28 Eingeleitet CapitalOne Overweight
2022-10-27 Eingeleitet Citigroup Buy
2022-08-15 Herabstufung Stifel Buy → Hold
2022-07-18 Fortgesetzt Oppenheimer Outperform
2022-03-10 Hochstufung Stifel Hold → Buy
2021-09-23 Eingeleitet Stifel Hold
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-03-11 Eingeleitet Guggenheim Buy
2020-10-07 Eingeleitet Wedbush Outperform
2020-09-01 Eingeleitet Northland Capital Outperform
2020-07-13 Hochstufung JP Morgan Neutral → Overweight
2020-06-17 Bestätigt H.C. Wainwright Buy
2020-04-06 Eingeleitet H.C. Wainwright Buy
2020-03-13 Eingeleitet ROTH Capital Buy
2019-10-17 Eingeleitet Oppenheimer Outperform
2019-09-10 Eingeleitet Robert W. Baird Outperform
2019-06-17 Eingeleitet Citigroup Buy
2019-06-17 Eingeleitet JP Morgan Neutral
2019-06-17 Eingeleitet Jefferies Buy
Alle ansehen

Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten

pulisher
Nov 22, 2024

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Yahoo Finance

Nov 22, 2024
pulisher
Nov 22, 2024

Jennison Associates LLC Buys 561,404 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Nov 22, 2024
pulisher
Nov 21, 2024

12 NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey

Nov 21, 2024
pulisher
Nov 21, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

Quest Partners LLC Increases Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Nov 21, 2024
pulisher
Nov 21, 2024

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Nov 21, 2024
pulisher
Nov 20, 2024

Finansavisen - Finansavisen

Nov 20, 2024
pulisher
Nov 20, 2024

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Analysts at Stephens - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Ideaya Biosciences Names Chief Commercial Officer - Contract Pharma

Nov 18, 2024
pulisher
Nov 18, 2024

IDEAYA Biosciences Taps Former Gilead Oncology VP as Chief Commercial Officer | IDYA Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Stephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN

Nov 18, 2024
pulisher
Nov 16, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowTime to Sell? - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Ideaya Biosciences stock hits 52-week low at $27.51 - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

500: Something went wrong - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

Ideaya Biosciences stock hits 52-week low at $27.51 By Investing.com - Investing.com UK

Nov 15, 2024
pulisher
Nov 14, 2024

Janus Henderson Group PLC's Strategic Acquisition in IDEAYA Bios - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

IDEAYA Biosciences' SWOT analysis: biotech stock's potential in uveal melanoma treatment - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

(IDYA) Investment Analysis - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of IDEAYA Biosciences Inc Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise - 뉴스와이어

Nov 12, 2024
pulisher
Nov 12, 2024

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - BioSpace

Nov 12, 2024
pulisher
Nov 12, 2024

IDEAYA Biosciences Announces Participation Jefferies London | Trending From Our Network - Chicago Star Media

Nov 12, 2024
pulisher
Nov 12, 2024

IDEAYA Biosciences to Present at Jefferies Conference, Host R&D Day in Late 2024 | IDYA Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - The Malaysian Reserve

Nov 11, 2024
pulisher
Nov 11, 2024

Ideaya nominates B7H3/PTK7 bispecific ADC as development candidate - BioWorld Online

Nov 11, 2024
pulisher
Nov 11, 2024

IDEAYA Announces Development Candidate Nomination of IDE034 | Trending From Our Network - Chicago Star Media

Nov 11, 2024
pulisher
Nov 09, 2024

Fiera Capital Corp Sells 45,590 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Research Analysts Set Expectations for IDYA FY2024 Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

90,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by General American Investors Co. Inc. - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

The 3.2% return this week takes IDEAYA Biosciences' (NASDAQ:IDYA) shareholders five-year gains to 258% - Simply Wall St

Nov 07, 2024
pulisher
Nov 07, 2024

Leerink Partnrs Issues Optimistic Estimate for IDYA Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

FY2024 EPS Forecast for IDEAYA Biosciences Raised by Analyst - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Leerink Partnrs Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Hold - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.5%Here's Why - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to Market Perform at Leerink Partners - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) - Yahoo Finance

Nov 05, 2024
pulisher
Nov 05, 2024

Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Nov 04, 2024
pulisher
Nov 03, 2024

abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com

Nov 01, 2024
pulisher
Oct 30, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com

Oct 30, 2024
pulisher
Oct 29, 2024

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - The Malaysian Reserve

Oct 28, 2024
pulisher
Oct 28, 2024

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors – Company AnnouncementFT.com - Financial Times

Oct 28, 2024

Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Kapitalisierung:     |  Volumen (24h):